Summary
A study published in Nature on September 9, 2026, introduces TRI-611, a selective, brain-penetrant molecular glue degrader of ALK. TRI-611 induces the degradation of ALK fusion proteins via a novel CRBN recruitment motif, showing preclinical anti-tumour activity and potential for treating ALK-positive non-small-cell lung cancer.